• Mashup Score: 0

    An interview with Christopher Starr, MD By Christine Yue Leonard, Senior Associate Editor D ry eye has a profound effect on quality of life. While we have a full armamentarium of treatments to offer patients, we can’ t always account for the impact of certain day-to-day lifestyle choices or situations when managing this chronic and often debilitating disease. Patients often want to know what else they can do to get through each day, in addition to the dry-eye treatments provided by their eye-care provider.

    Tweet Tweets with this article
    • Highlights from the TFOS Lifestyle Reports A selection of key takeaways from the largest global dry-eye panel to date. https://t.co/bAFYJa8GLV #ophthalmology #eyecare #dryeye #cornea #dryeyedisease #TFOSLifestyle #TFOS #ophthalmologist #vision https://t.co/04cwpMsDFn

  • Mashup Score: 0

    In a remarkable feat of engineering and scientific ingenuity, researchers at the Champalimaud Foundation have devised a first-of-its-kind setup for delivering complex visual stimuli within the limiting confines of a rodent Magnetic Resonance Imaging (MRI) scanner. This enabled them to open new vistas in understanding adult plasticity in the brain’s visual pathways, with implications for the fields of adult brain rehabilitation and visual restoration therapies.

    Tweet Tweets with this article
    • Researchers @ChampalimaudF devised a first-of-its-kind setup for delivering complex visual stimuli within the limiting confines of a #rodent Magnetic Resonance Imaging (#MRI) scanner #neuroplasticity #animalresearch #vision https://t.co/Z9WyWn4jqx

  • Mashup Score: 0

    By Andrew Beers, Associate Editor T he presbyopia marketplace is growing, but physicians and patients ar en’ t satisfied with some of the latest advancements in presbyopic treatments. Allergan offers the first presbyopia-correcting eye drop in the market, Vuity, and yet prescriptions have been trailing off since its release. Why is Vuity struggling to satisfy patients, and how can the pharmaceutical market bounce back? John Hovanesian, MD, an ophthalmologist at Harvard Eye Associates in Laguna Hills,

    Tweet Tweets with this article
    • Whither Presbyopia Eye Drops?💧 Vuity is struggling on the market, but it might not be the end of presbyopia-correcting eye drops. Here’s a look at the current market and pipeline. https://t.co/pvk0uPSnka #ophthalmology #ophthalmologist #vision #vuity #allergan #presbyopia https://t.co/DFCV8tz2mz

  • Mashup Score: 1

    By Erik Massenzio, MD, Christian Ponder, MD, and Mark Moster, MD A 63-year-old Caucasian female is referred to the Wills Eye Emergency Room after six days of vision loss in her right eye. She complains of pain with right eye movements, and notes she had a headache two weeks ago which has since resolved. She denies diplopia, jaw claudication, weight loss, scalp tenderness, polymyalgia, systemic neurologic symptoms or snoring. The patient had no significant past ocular history or past medical history. Past

    Tweet Tweets with this article
    • August 2023 Wills Eye Resident Case Series A 63-year-old Caucasian female is referred to the Wills Eye ER after six days of vision loss in her right eye. https://t.co/NOTsQfMa5J @Wills_Eye #willseye #willseyehospital #ophthalmology #ophthalmologist #vision https://t.co/zw8FkUv0Q7

  • Mashup Score: 0

    In a discussion between Alicia Morgans and Karim Fizazi, they explore the quality of life outcomes from the VISION trial, published in Lancet Oncology. This Phase III trial examines the effects of Lutetium-PSMA-617 (also known as Pluvicto) on heavily pretreated metastatic castration-resistant prostate cancer patients. The study demonstrates a significant 38% reduction in the risk of death….

    Tweet Tweets with this article
    • From the #VISION trial: Improved patient outcomes with lutetium-PSMA-617. Karim Fizazi, MD, PhD @GustaveRoussy joins @CaPsurvivorship @DanaFarber in this discussion on the quality of life outcomes from the VISION trial, published in @TheLancetOncol > https://t.co/oyV97QM19P https://t.co/cadr2QUlty

  • Mashup Score: 0

    In a discussion between Alicia Morgans and Karim Fizazi, they explore the quality of life outcomes from the VISION trial, published in Lancet Oncology. This Phase III trial examines the effects of Lutetium-PSMA-617 (also known as Pluvicto) on heavily pretreated metastatic castration-resistant prostate cancer patients. The study demonstrates a significant 38% reduction in the risk of death….

    Tweet Tweets with this article
    • From the #VISION trial: Improved patient outcomes with lutetium-PSMA-617. Karim Fizazi, MD, PhD @GustaveRoussy joins @CaPsurvivorship @DanaFarber in this discussion on the quality of life outcomes from the VISION trial, published in @TheLancetOncol > https://t.co/oyV97QM19P https://t.co/5QBdVljTLu